Novel risk factors related to cancer in scleroderma

Autoimmunity Reviews

Volumn 16, Issue 5, 2017, Pages 461-468

  Bernal Bello, David ^a   de Tena, Jaime García ^b   Guillén del Castillo, Alfredo ^c   Selva O'Callaghan, Albert ^c   Callejas Moraga, Eduardo L ^c   Marín Sánchez, Ana María ^c   Fonollosa Pla, Vicent ^c   Simeón Aznar, Carmen Pilar ^c  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Anti PM scl antibodies; Aspirin; Cancer; Exosome; Systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA DIRECTED RNA POLYMERASE III; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; CANCER RISK; CANCER SURVIVAL; CAPILLAROSCOPY; CLINICAL FEATURE; COHORT ANALYSIS; CONCEPTION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; EXOSOME; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SMOKING; SYSTEMIC SCLEROSIS; COMPLICATION; NEOPLASMS; PATHOLOGY;

ADULT; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 85017156511     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.03.012     Document Type: Review

References (107)

1. [1] Zintzaras, E., Voulgarelis, M., Moutsopoulos, H.M., The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165 (2005), 2337–2344, 10.1001/archinte.165.20.2337.
2. [2] Yu, K.-H., Kuo, C.-F., Huang, L.H., Huang, W.-K., See, L.-C., Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a nationwide population-based dynamic cohort study in Taiwan. Medicine (Baltimore), 95, 2016, e3540, 10.1097/MD.0000000000003540.
3. [3] Kiss, E., Kovacs, L., Szodoray, P., Malignancies in systemic lupus erythematosus. Autoimmun Rev 9 (2010), 195–199, 10.1016/j.autrev.2009.07.004.
4. [4] Cao, L., Tong, H., Xu, G., Liu, P., Meng, H., Wang, J., et al. Systemic lupus erythematous and malignancy risk: a meta-analysis. PLoS One, 10, 2015, e0122964, 10.1371/journal.pone.0122964.
5. [5] Yang, Z., Lin, F., Qin, B., Liang, Y., Zhong, R., Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42 (2015), 282–291, 10.3899/jrheum.140566.
6. [6] Olazagasti, J.M., Baez, P.J., Wetter, D.A., Ernste, F.C., Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol 16 (2015), 89–98, 10.1007/s40257-015-0120-1.
7. [7] Qiang, J.K., Kim, W.B., Baibergenova, A., Alhusayen, R., Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg, 2016, 10.1177/1203475416665601 [Epub ahead of print].
8. [8] Liang, Y., Yang, Z., Qin, B., Zhong, R., Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73 (2014), 1151–1156, 10.1136/annrheumdis-2013-203305.
9. [9] Smitten, A.L., Simon, T.A., Hochberg, M.C., Suissa, S., A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther, 10, 2008, R45, 10.1186/ar2404.
10. [10] Simon, T.A., Thompson, A., Gandhi, K.K., Hochberg, M.C., Suissa, S., Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther, 17, 2015, 212, 10.1186/s13075-015-0728-9.
11. [11] Shang, W., Ning, Y., Xu, X., Li, M., Guo, S., Han, M., et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One, 10, 2015, e0126016, 10.1371/journal.pone.0126016.
12. [12] Onishi, A., Sugiyama, D., Kumagai, S., Morinobu, A., Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65 (2013), 1913–1921, 10.1002/art.37969.
13. [13] Bonifazi, M., Tramacere, I., Pomponio, G., Gabrielli, B., Avvedimento, E.V., La Vecchia, C., et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 52 (2013), 143–154, 10.1093/rheumatology/kes303.
14. [14] Zhang, J.-Q., Wan, Y.-N., Peng, W.-J., Yan, J.-W., Li, B.-Z., Mei, B., et al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol 37 (2013), 523–527, 10.1016/j.canep.2013.04.014.
15. [15] Duncan, S.C., Winkelmann, R.K., Cancer and scleroderma. Arch Dermatol 115 (1979), 950–955.
16. [16] Black, K.A., Zilko, P.J., Dawkins, R.L., Armstrong, B.K., Mastaglia, G.L., Cancer in connective tissue disease. Arthritis Rheum 25 (1982), 1130–1133.
17. [17] Chatterjee, S., Dombi, G.W., Severson, R.K., Mayes, M.D., Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 52 (2005), 2415–2424, 10.1002/art.21225.
18. [18] Hashimoto, A., Arinuma, Y., Nagai, T., Tanaka, S., Matsui, T., Tohma, S., et al. Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med 51 (2012), 1683–1688, 10.2169/internalmedicine.51.7686.
19. [19] Shah, A.A., Casciola-Rosen, L., Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol 27 (2015), 563–570, 10.1097/BOR.0000000000000222.
20. [20] Smedby, K.E., Baecklund, E., Askling, J., Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 15 (2006), 2069–2077, 10.1158/1055-9965.EPI-06-0300.
21. [21] Rosenthal, A.K., McLaughlin, J.K., Gridley, G., Nyrén, O., Incidence of cancer among patients with systemic sclerosis. Cancer 76 (1995), 910–914, 10.1002/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T.
22. [22] Olesen, A.B., Svaerke, C., Farkas, D.K., Sørensen, H.T., Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 163 (2010), 800–806, 10.1111/j.1365-2133.2010.09861.x.
23. [23] Gulamhusein, A., Pope, J.E., Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil. J Rheumatol 36 (2009), 460–462, 10.3899/jrheum.080611.
24. [24] Travis, L.B., Curtis, R.E., Glimelius, B., Holowaty, E.J., Van Leeuwen, F.E., Lynch, C.F., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. JNCI J Natl Cancer Inst 87 (1995), 524–531, 10.1093/jnci/87.7.524.
25. [25] Faurschou, M., Mellemkjaer, L., Voss, A., Keller, K.K., Hansen, I.T., Baslund, B., Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 54 (2015), 1345–1350, 10.1093/rheumatology/keu372.
26. [26] Radis, C.D., Kahl, L.E., Baker, G.L., Wasko, M.C., Cash, J.M., Gallatin, A., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 38 (1995), 1120–1127.
27. [27] Dreyer, L., Faurschou, M., Mogensen, M., Jacobsen, S., High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term follow up study in a Danish cohort. Arthritis Rheum 63 (2011), 3032–3037, 10.1002/art.30483.
28. [28] DePry, J.L., Reed, K.B., Cook-Norris, R.H., Brewer, J.D., Iatrogenic immunosuppression and cutaneous malignancy. Clin Dermatol 29 (2011), 602–613, 10.1016/j.clindermatol.2011.08.009.
29. [29] Pontifex, E.K., Hill, C.L., Roberts-Thomson, P., Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 66 (2007), 551–553, 10.1136/ard.2006.056424.
30. [30] Bernal-Bello, D., García de Tena, J., Simeón-Aznar, C., Fonollosa-Pla, V., Systemic sclerosis, breast cancer and calcium channel blockers: a new player on the scene?. Autoimmun Rev 13 (2014), 880–881, 10.1016/j.autrev.2014.03.003.
31. [31] Jacobsen, S., Halberg, P., Ullman, S., Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37 (1998), 750–755.
32. [32] Hesselstrand, R., Scheja, A., Akesson, A., Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57 (1998), 682–686.
33. [33] Tyndall, A.J., Bannert, B., Vonk, M., Airò, P., Cozzi, F., Carreira, P.E., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis 69 (2010), 1809–1815, 10.1136/ard.2009.114264.
34. [34] Elhai, M., Meune, C., Avouac, J., Kahan, A., Allanore, Y., Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 51 (2012), 1017–1026, 10.1093/rheumatology/ker269.
35. [35] Simeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, C., Espinosa-Garriga, G., Campillo-Grau, M., Ramos-Casals, M., et al. Registry of the Spanish network for systemic sclerosis: survival, prognostic factors, and causes of death. Medicine (Baltimore), 94, 2015, e1728, 10.1097/MD.0000000000001728.
36. [36] Simeon, C.-P., Armadans, L., Fonollosa, V., Vilardell, M., Candell, J., Tolosa, C., et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 56 (1997), 723–728, 10.1136/ard.56.12.723.
37. [37] Walker, U.A., Tyndall, A., Czirják, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66 (2007), 754–763, 10.1136/ard.2006.062901.
38. [38] Hashimoto, A., Tejima, S., Tono, T., Suzuki, M., Tanaka, S., Matsui, T., et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 38 (2011), 1931–1939, 10.3899/jrheum.100298.
39. [39] Alba, M.A., Velasco, C., Simeón, C.P., Fonollosa, V., Trapiella, L., Egurbide, M.V., et al. Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore) 93 (2014), 73–81, 10.1097/MD.0000000000000018.
40. [40] LeRoy, E.C., Medsger, T.A., Criteria for the classification of early systemic sclerosis. J Rheumatol 28 (2001), 1573–1576.
41. [41] Simeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, C., Espinosa-Garriga, G., Ramos-Casals, M., Campillo-Grau, M., et al. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum 41 (2012), 789–800, 10.1016/j.semarthrit.2011.10.004.
42. [42] Maricq, H.R., Spencer-Green, G., LeRoy, E.C., Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med 61 (1976), 862–870.
43. [43] Rönnelid, J., Barbasso Helmers, S., Storfors, H., Grip, K., Rönnblom, L., Franck-Larsson, K., et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 9 (2009), 58–61, 10.1016/j.autrev.2009.03.005.
44. [44] Ghirardello, A., Rampudda, M., Ekholm, L., Bassi, N., Tarricone, E., Zampieri, S., et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology 49 (2010), 2370–2374, 10.1093/rheumatology/keq281.
45. [45] Patterson, K.A., Roberts-Thomson, P.J., Lester, S., Tan, J.A., Hakendorf, P., Rischmueller, M., et al. Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis. Arthritis Rheumatol 67 (2015), 3234–3244, 10.1002/art.39316.
46. [46] Derk, C.T., Rasheed, M., Artlett, C.M., Jimenez, S.A., A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 33 (2006), 1113–1116.
47. [47] Higuchi, M., Horiuchi, T., Ishibashi, N., Yoshizawa, S., Niho, Y., Nagasawa, K., Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 19 (2000), 123–126.
48. [48] Hill, C.L., Nguyen, A.-M., Roder, D., Roberts-Thomson, P., Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62 (2003), 728–731.
49. [49] Shah, A.A., Casciola-Rosen, L., Rosen, A., Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol (Hoboken, NJ) 67 (2015), 317–326, 10.1002/art.38928.
50. [50] Shah, A.A., Rosen, A., Hummers, L., Wigley, F., Casciola-Rosen, L., Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62 (2010), 2787–2795, 10.1002/art.27549.
51. [51] Airo', P., Ceribelli, A., Cavazzana, I., Taraborelli, M., Zingarelli, S., Franceschini, F., Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38 (2011), 1329–1334, 10.3899/jrheum.101144.
52. [52] Nikpour, M., Hissaria, P., Byron, J., Sahhar, J., Micallef, M., Paspaliaris, W., et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther, 13, 2011, R211, 10.1186/ar3544.
53. [53] Abu-Shakra, M., Guillemin, F., Lee, P., Cancer in systemic sclerosis. Arthritis Rheum 36 (1993), 460–464, 10.1002/art.1780360405.
54. [54] Shah, A.A., Hummers, L.K., Casciola-Rosen, L., Visvanathan, K., Rosen, A., Wigley, F.M., Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol 67 (2015), 1053–1061, 10.1002/art.39022.
55. [55] Roumm, A.D., Medsger, T.A., Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 28 (1985), 1336–1340.
56. [56] Szekanecz, É., Szamosi, S., Horváth, Á., Németh, Á., Juhász, B., Szántó, J., et al. Malignancies associated with systemic sclerosis. Autoimmun Rev 11 (2012), 852–855, 10.1016/j.autrev.2012.02.021.
57. [57] Goobie, G.C., Bernatsky, S., Ramsey-Goldman, R., Clarke, A.E., Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol 27 (2015), 454–460, 10.1097/BOR.0000000000000202.
58. [58] Llorca, J., Lopez-Diaz, M.J., Gonzalez-Juanatey, C., Ollier, W.E.R., Martin, J., Gonzalez-Gay, M.A., Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37 (2007), 31–38, 10.1016/j.semarthrit.2007.01.002.
59. [59] Wipff, J., Coriat, R., Masciocchi, M., Caramaschi, P., Derk, C.T., Hachulla, E., et al. Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR scleroderma trials and research prospective follow-up study. Rheumatology 50 (2011), 1440–1444, 10.1093/rheumatology/ker110.
60. [60] Kastelein, F., Spaander, M.C.W., Steyerberg, E.W., Biermann, K., Valkhoff, V.E., Kuipers, E.J., et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 11 (2013), 382–388, 10.1016/j.cgh.2012.11.014.
61. [61] El-Serag, H.B., Aguirre, T.V., Davis, S., Kuebeler, M., Bhattacharyya, A., Sampliner, R.E., Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99 (2004), 1877–1883, 10.1111/j.1572-0241.2004.30228.x.
62. [62] Hillman, L.C., Chiragakis, L., Shadbolt, B., Kaye, G.L., Clarke, A.C., Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 180 (2004), 387–391.
63. [63] Moinzadeh, P., Fonseca, C., Hellmich, M., Shah, A.A., Chighizola, C., Denton, C.P., et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther, 16, 2014, R53, 10.1186/ar4486.
64. [64] Joseph, C.G., Darrah, E., Shah, A.A., Skora, A.D., Casciola-Rosen, L.A., Wigley, F.M., et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343 (2014), 152–157, 10.1126/science.1246886.
65. [65] Mahler, M., Raijmakers, R., Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 6 (2007), 432–437, 10.1016/j.autrev.2007.01.013.
66. [66] Koschik, R.W., Fertig, N., Lucas, M.R., Domsic, R.T., Medsger, T.A., Anti-PM-Scl antibody in patients with systemic sclerosis. Clin. Exp. Rheumatol. 30 (2012), S12–S16.
67. [67] Wodkowski, M., Hudson, M., Proudman, S., Walker, J., Stevens, W., Nikpour, M., et al. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity 48 (2015), 542–551, 10.3109/08916934.2015.1077231.
68. [68] Guillen-Del Castillo, A., Pilar Simeón-Aznar, C., Fonollosa-Pla, V., Alonso-Vila, S., Reverte-Vinaixa, M.M., Muñoz, X., et al. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. Semin Arthritis Rheum 44 (2014), 331–337, 10.1016/j.semarthrit.2014.07.002.
69. [69] D'Aoust, J., Hudson, M., Tatibouet, S., Wick, J., Mahler, M., Baron, M., et al. Clinical and serologic correlates of anti-PM/scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 66 (2014), 1608–1615, 10.1002/art.38428.
70. [70] Maes, L., Blockmans, D., Verschueren, P., Westhovens, R., De Beéck, K.O., Vermeersch, P., et al. Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma. Clin Chim Acta 411 (2010), 965–971, 10.1016/j.cca.2010.03.018.
71. [71] Kinlen, L.J., Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78 (1985), 44–49.
72. [72] Bernatsky, S., Clarke, A.E., Suissa, S., Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168 (2008), 378–381, 10.1001/archinternmed.2007.107.
73. [73] Knight, A., Askling, J., Ekbom, A., Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 100 (2002), 82–85, 10.1002/ijc.10444.
74. [74] O'Neill, J.O., Edwards, L.B., Taylor, D.O., Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25 (2006), 1186–1191, 10.1016/j.healun.2006.06.010.
75. [75] Ramirez, G.A., Franchini, S., Rovere-Querini, P., Sabbadini, M.G., Manfredi, A.A., Maugeri, N., The role of platelets in the pathogenesis of systemic sclerosis. Front Immunol, 3, 2012, 160, 10.3389/fimmu.2012.00160.
76. [76] Pattanaik, D., Brown, M., Postlethwaite, B.C., Postlethwaite, A.E., Pathogenesis of systemic sclerosis. Front Immunol, 6, 2015, 272, 10.3389/fimmu.2015.00272.
77. [77] Santilli, F., Boccatonda, A., Davì, G., Aspirin, platelets, and cancer: the point of view of the internist. Eur J Intern Med 34 (2016), 11–20, 10.1016/j.ejim.2016.06.004.
78. [78] Lim, W.-Y., Chuah, K.L., Eng, P., Leong, S.S., Lim, E., Lim, T.K., et al. Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer. Lung Cancer 77 (2012), 246–251, 10.1016/j.lungcan.2012.03.005.
79. [79] Bosco, J.L.F., Palmer, J.R., Boggs, D.A., Hatch, E.E., Rosenberg, L., Regular aspirin use and breast cancer risk in US black women. Cancer Causes Control 22 (2011), 1553–1561, 10.1007/s10552-011-9832-6.
80. [80] Famenini, S., Young, L.C., Aspirin use and melanoma risk: a review of the literature. J Am Acad Dermatol 70 (2014), 187–191, 10.1016/j.jaad.2013.09.045.
81. [81] Zhang, D., Bai, B., Xi, Y., Wang, T., Zhao, Y., Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Gynecol Oncol, 2016, 10.1016/j.ygyno.2016.04.543.
82. [82] Singh, Ranger G., The role of aspirin in colorectal cancer chemoprevention. Crit Rev Oncol Hematol 104 (2016), 87–90, 10.1016/j.critrevonc.2016.05.011.
83. [83] Kauppi, M., Pukkala, E., Isomäki, H., Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 14 (1996), 551–553.
84. [84] Bernatsky, S., Ramsey-Goldman, R., Labrecque, J., Joseph, L., Boivin, J.-F., Petri, M., et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42 (2013), 130–135, 10.1016/j.jaut.2012.12.009.
85. [85] Patrignani, P., Patrono, C., Aspirin and cancer. J Am Coll Cardiol 68 (2016), 967–976, 10.1016/j.jacc.2016.05.083.
86. [86] Ulrych, T., Böhm, A., Polzin, A., Daum, G., Nüsing, R.M., Geisslinger, G., et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 9 (2011), 790–798, 10.1111/j.1538-7836.2011.04194.x.
87. [87] Rubio-Rivas, M., Royo, C., Simeón, C.P., Corbella, X., Fonollosa, V., Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44 (2014), 208–219, 10.1016/j.semarthrit.2014.05.010.
88. [88] Hachulla, E., Carpentier, P., Gressin, V., Diot, E., Allanore, Y., Sibilia, J., et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology 48 (2009), 304–308, 10.1093/rheumatology/ken488.
89. [89] Muro, Y., Hosono, Y., Sugiura, K., Ogawa, Y., Mimori, T., Akiyama, M., Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 17 (2015), 1–10, 10.1186/s13075-015-0573-x.
90. [90] Vandergheynst, F., Ocmant, A., Sordet, C., Humbel, R.L., Goetz, J., Roufosse, F., et al. Anti-pm/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin. Exp. Rheumatol. 24 (2006), 129–133.
91. [91] Selva-O'Callaghan, A., Labrador-Horrillo, M., Solans-Laque, R., Simeon-Aznar, C.P., Martínez-Gómez, X., Vilardell-Tarrés, M., Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 55 (2006), 791–798, 10.1002/art.22237.
92. [92] Marie, I., Lahaxe, L., Benveniste, O., Delavigne, K., Adoue, D., Mouthon, L., et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 162 (2010), 337–344, 10.1111/j.1365-2133.2009.09484.x.
93. [93] Chinoy, H., Fertig, N., Oddis, C.V., Ollier, W.E.R., Cooper, R.G., The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66 (2007), 1345–1349, 10.1136/ard.2006.068502.
94. [94] Bruni, C., Lages, A., Patel, H., Nihtyanova, S.I., Green, B., AbuHilal, M., et al. Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour. Rheumatology, 2016, kew382, 10.1093/rheumatology/kew382 [Epub ahead of print].
95. [95] Cabrera, C.M., Fernández-Grande, E., Urra, J.M., Serological profile and clinical features of nucleolar antinuclear pattern in patients with systemic lupus erythematosus from southwestern Spain. Lupus 25 (2016), 980–987, 10.1177/0961203316629557.
96. [96] Altintas, A., Cil, T., Pasa, S., Danis, R., Kilinc, I., Ayyildiz, O., et al. Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and non-Hodgkin's lymphoma: a single center experience. Minerva Med 99 (2008), 7–14.
97. [97] Raijmakers, R., Renz, M., Wiemann, C., Egberts, W.V., Seelig, H.P., van Venrooij, W.J., et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 50 (2004), 565–569, 10.1002/art.20056.
98. [98] Brouwer, R., Pruijn, G.J., van Venrooij, W.J., The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Res 3 (2001), 102–106, 10.1186/ar147.
99. [99] van den Boorn, J.G., Dassler, J., Coch, C., Schlee, M., Hartmann, G., Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev 65 (2013), 331–335, 10.1016/j.addr.2012.06.011.
100. [100] Schilders, G., van Dijk, E., Raijmakers, R., Pruijn, G.J.M., Cell and molecular biology of the exosome: how to make or break an RNA. Int Rev Cytol 251 (2006), 159–208, 10.1016/S0074-7696(06)51005-8.
101. [101] Yang, X.-F., Wu, C.J., Chen, L., Alyea, E.P., Canning, C., Kantoff, P., et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 62 (2002), 5517–5522.
102. [102] Staals, R.H.J., Pruijn, G.J.M., The human exosome and disease. Adv Exp Med Biol 702 (2011), 132–142, 10.1007/978-1-4419-7841-7_11.
103. [103] Azmi, A.S., Bao, B., Sarkar, F.H., Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev 32 (2013), 623–642, 10.1007/s10555-013-9441-9.
104. [104] Melo, S.A., Sugimoto, H., O'Connell, J.T., Kato, N., Villanueva, A., Vidal, A., et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26 (2014), 707–721, 10.1016/j.ccell.2014.09.005.
105. [105] Grange, C., Tapparo, M., Collino, F., Vitillo, L., Damasco, C., Deregibus, M.C., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 71 (2011), 5346–5356, 10.1158/0008-5472.CAN-11-0241.
106. [106] Kucharzewska, P., Christianson, H.C., Welch, J.E., Svensson, K.J., Fredlund, E., Ringnér, M., et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A 110 (2013), 7312–7317, 10.1073/pnas.1220998110.
107. [107] Fu, H., Yang, H., Zhang, X., Xu, W., The emerging roles of exosomes in tumor–stroma interaction. J Cancer Res Clin Oncol 142 (2016), 1897–1907, 10.1007/s00432-016-2145-0.